Eleva Capital’s Fennec Pharmaceuticals FENC Stock Holding History

Eleva Capital’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$327K	Hold	53,234	–	–	0.1%	18
2026 Q1	$327K	Buy	+53,234	New	+$411K	0.1%	18

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Eleva Capital's FENC Position: Q2 2026 in Review

Eleva Capital held its Fennec Pharmaceuticals (FENC) position steady in Q2 2026 at 53,234 shares worth $327K. The position accounts for 0.1% of the portfolio, ranked #18.

Eleva Capital first reported a position in FENC in Q1 2026 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Eleva Capital held 53,234 shares of Fennec Pharmaceuticals worth $327K as of Q2 2026.
Eleva Capital left its Fennec Pharmaceuticals share count unchanged in Q2 2026.
Fennec Pharmaceuticals made up 0.1% of Eleva Capital's portfolio in Q2 2026, its #18 holding.
Eleva Capital first reported a position in Fennec Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Eleva Capital's 13F filing for Q2 2026, filed 2 Jul 2026.